Miatmoko Andang, Octavia Rifda Tarimi, Araki Tamasa, Annoura Takeshi, Sari Retno
Department of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Campus C UNAIR Mulyorejo, Surabaya 60115, Indonesia.
Stem Cell Research and Development Center, Universitas Airlangga, 2 Floor Institute of Tropical Disease Building, Campus C UNAIR Mulyorejo, Surabaya 60115, Indonesia.
Saudi Pharm J. 2024 Jun;32(6):102085. doi: 10.1016/j.jsps.2024.102085. Epub 2024 Apr 24.
This review discusses the potential of liposomes as drug delivery systems for antimalarial therapies. Malaria continues to be a significant cause of mortality and morbidity, particularly among children and pregnant women. Drug resistance due to patient non-compliance and troublesome side effects remains a significant challenge in antimalarial treatment. Liposomes, as targeted and efficient drug carriers, have garnered attention owing to their ability to address these issues. Liposomes encapsulate hydrophilic and/or hydrophobic drugs, thus providing comprehensive and suitable therapeutic drug delivery. Moreover, the potential of passive and active drug delivery enables drug concentration in specific target tissues while reducing adverse effects. However, successful liposome formulation is influenced by various factors, including drug physicochemical characteristics and physiological barriers encountered during drug delivery. To overcome these challenges, researchers have explored modifications in liposome nanocarriers to achieve efficient drug loading, controlled release, and system stability. Computational approaches have also been adopted to predict liposome system stability, membrane integrity, and drug-liposome interactions, improving formulation development efficiency. By leveraging computational methods, optimizing liposomal drug delivery systems holds promise for enhancing treatment efficacy and minimizing side effects in malaria therapy. This review consolidates the current understanding and highlights the potential of liposome strategies against malaria.
本综述探讨了脂质体作为抗疟治疗药物递送系统的潜力。疟疾仍然是导致死亡和发病的重要原因,尤其是在儿童和孕妇中。由于患者不依从导致的耐药性以及令人困扰的副作用,仍然是抗疟治疗中的重大挑战。脂质体作为靶向且高效的药物载体,因其能够解决这些问题而受到关注。脂质体可包裹亲水性和/或疏水性药物,从而提供全面且合适的治疗药物递送。此外,被动和主动药物递送的潜力能够使药物在特定靶组织中富集,同时减少不良反应。然而,脂质体制剂的成功受到多种因素影响,包括药物的物理化学特性以及药物递送过程中遇到的生理屏障。为克服这些挑战,研究人员探索了对脂质体纳米载体的修饰,以实现高效载药、控释和系统稳定性。还采用了计算方法来预测脂质体系统稳定性、膜完整性以及药物 - 脂质体相互作用,提高制剂开发效率。通过利用计算方法,优化脂质体药物递送系统有望提高疟疾治疗的疗效并将副作用降至最低。本综述巩固了当前的认识,并突出了脂质体抗疟策略的潜力。